U.S. stock night trading fluctuations: Climb Bio surged 10.33% in after-hours trading, with active capital inflows attracting market attention

U.S. Stock Night Market Movements Climb Bio rose 10.33% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry VistaGen Therapeutics rose 6.82% in the night market, with a trading volume of $168,900, and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Recursion Pharmaceuticals had a trading volume of $163,900, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Moderna fell 0.81% in the night market. Based on recent news, On December 12, Moderna co-founder Noubar Afeyan emphasized the vaccine's safety during the FDA investigation into vaccine-related deaths, stating that the vaccine prevented nearly 20 million deaths globally in its first year. This statement aimed to alleviate market concerns about vaccine safety but failed to fully dispel investor doubts, leading to a decline in stock price. On December 12, analyst Tsai pointed out that Moderna's path to cash flow breakeven by 2028 is unclear, relying on sustained annual revenue growth and faster expense reductions. Analysts are cautious about the potential for new product approvals, maintaining a "Hold" rating with a target price of $29. This analysis report has increased market concerns about the company's future financial performance, further pressuring the stock price. On December 12, Jefferies initiated coverage of Moderna with a "Hold" rating and a target price of $30. The analysts' cautious stance reflects market concerns about the company's future growth prospects, putting pressure on the stock price. The development of the mRNA sector is accompanied by fluctuations in confidence, leading to significant market volatility